TY - JOUR
T1 - Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction
T2 - An NRG Oncology/Gynecologic Oncology Group study
AU - Eskander, Ramez N.
AU - Kauderer, James
AU - Tewari, Krishnansu S.
AU - Mannel, Robert S.
AU - Bristow, Robert E.
AU - O'Malley, David M.
AU - Rubin, Stephen C.
AU - Glaser, Gretchen E.
AU - Hamilton, Chad A.
AU - Fujiwara, Keiichi
AU - Huh, Warner K.
AU - Ueland, Frederick
AU - Stephan, Jean Marie
AU - Burger, Robert A.
N1 - Publisher Copyright:
© 2018
PY - 2018/6
Y1 - 2018/6
N2 - Purpose: We sought to determine the level of concordance among surgeons' assessment of residual disease (RD) and pre-treatment computed tomography (CT) findings among women who underwent optimal surgical cytoreduction for advanced stage ovarian cancer. Methods: This is a post-trial ad hoc analysis of a phase 3 randomized clinical trial evaluating the impact of bevacizumab in primary and maintenance therapy for patients with advanced stage ovarian cancer following surgical cytoreduction. All subjects underwent imaging of the chest/abdomen/pelvis to establish a post-surgical baseline prior to the initiation of chemotherapy. Information collected on trial was utilized to compare surgeon's operative assessment of RD, to pre-treatment imaging. Results: Of 1873 enrolled patients, surgical outcome was described as optimal (RD ≤ 1 cm) in 639 subjects. Twelve patients were excluded as they did not have a baseline, pretreatment imaging, leaving 627 participants for analysis. The average interval from surgery to baseline scan was 26 days (range: 1–109). In 251 cases (40%), the post-operative scan was discordant with surgeon assessment, demonstrating RD > 1 cm in size. RD > 1 cm was most commonly identified in the right upper quadrant (28.4%), retroperitoneal para-aortic lymph nodes (RD > 1.5 cm; 28.2%) and the left upper quadrant (10.7%). Patients with RD > 1 cm on pre-treatment CT (discordant) exhibited a significantly greater risk of disease progression (HR 1.30; 95% CI 1.08–1.56; p = 0.0059). Conclusions: Among patients reported to have undergone optimal cytoreduction, 40% were found to have lesions >1 cm on postoperative, pretreatment imaging. Although inflammatory changes and/or rapid tumor regrowth could account for the discordance, the impact on PFS and distribution of RD may suggest underestimation by the operating surgeon.
AB - Purpose: We sought to determine the level of concordance among surgeons' assessment of residual disease (RD) and pre-treatment computed tomography (CT) findings among women who underwent optimal surgical cytoreduction for advanced stage ovarian cancer. Methods: This is a post-trial ad hoc analysis of a phase 3 randomized clinical trial evaluating the impact of bevacizumab in primary and maintenance therapy for patients with advanced stage ovarian cancer following surgical cytoreduction. All subjects underwent imaging of the chest/abdomen/pelvis to establish a post-surgical baseline prior to the initiation of chemotherapy. Information collected on trial was utilized to compare surgeon's operative assessment of RD, to pre-treatment imaging. Results: Of 1873 enrolled patients, surgical outcome was described as optimal (RD ≤ 1 cm) in 639 subjects. Twelve patients were excluded as they did not have a baseline, pretreatment imaging, leaving 627 participants for analysis. The average interval from surgery to baseline scan was 26 days (range: 1–109). In 251 cases (40%), the post-operative scan was discordant with surgeon assessment, demonstrating RD > 1 cm in size. RD > 1 cm was most commonly identified in the right upper quadrant (28.4%), retroperitoneal para-aortic lymph nodes (RD > 1.5 cm; 28.2%) and the left upper quadrant (10.7%). Patients with RD > 1 cm on pre-treatment CT (discordant) exhibited a significantly greater risk of disease progression (HR 1.30; 95% CI 1.08–1.56; p = 0.0059). Conclusions: Among patients reported to have undergone optimal cytoreduction, 40% were found to have lesions >1 cm on postoperative, pretreatment imaging. Although inflammatory changes and/or rapid tumor regrowth could account for the discordance, the impact on PFS and distribution of RD may suggest underestimation by the operating surgeon.
KW - GOG
KW - NRG
KW - Ovarian cancer
KW - Radiographic evaluation
KW - Surgeon's assessment
KW - Surgical cytoreduction
UR - http://www.scopus.com/inward/record.url?scp=85043592471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043592471&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2018.03.043
DO - 10.1016/j.ygyno.2018.03.043
M3 - Article
C2 - 29550184
AN - SCOPUS:85043592471
SN - 0090-8258
VL - 149
SP - 525
EP - 530
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -